Surviving prostate cancer is a victory. But for many men, the weeks and months after treatment bring an unexpected challenge: erectile dysfunction (ED). Whether you underwent radical prostatectomy, radiotherapy, or hormone therapy, the impact on sexual function is real, well-documented, and — critically — something that can be addressed.
Surviving prostate cancer is a victory. But for many men, the weeks and months after treatment bring an unexpected challenge: erectile dysfunction (ED). Whether you underwent radical prostatectomy, radiotherapy, or hormone therapy, the impact on sexual function is real, well-documented, and — critically — something that can be addressed.
This article explains why ED occurs after prostate cancer treatment, what the recovery timeline looks like, and which evidence-based interventions are available.
The prostate gland sits at the base of the bladder, surrounded by the neurovascular bundles responsible for producing an erection. During treatment, these structures are at risk.
Radical prostatectomy (surgical removal of the prostate)
Even with nerve-sparing techniques, the cavernous nerves running alongside the prostate are stretched, bruised, or — in non-nerve-sparing cases — severed during surgery. This causes a temporary or permanent disruption to the neural signalling that triggers erections. Studies show that ED rates following radical prostatectomy range from 25% to over 85%, depending on the surgical approach, nerve-sparing status, and the patient's pre-operative function.¹
Radiotherapy (external beam or brachytherapy)
Radiation damages the small blood vessels that supply the erectile tissue of the penis over time. Unlike surgery, the onset of ED after radiotherapy tends to be gradual — often appearing 12–24 months post-treatment — and is associated with progressive vascular insufficiency.²
Androgen deprivation therapy (ADT)
ADT lowers testosterone, which plays a central role in libido and erectile function. Men on ADT frequently report loss of sexual desire alongside reduced erection quality. These effects typically persist for the duration of hormone therapy, though partial recovery may occur after treatment ends.³
One of the most important things to understand about post-prostatectomy ED is that nerve recovery is slow. Even when both neurovascular bundles are preserved, the cavernous nerves can take 12–24 months — sometimes longer — to recover full function.
During this period, the erectile tissue in the penis is deprived of the oxygenation that normal erections provide. Without regular erections (even nocturnal ones), smooth muscle cells in the corpora cavernosa can be replaced by fibrotic tissue — a process called corporal fibrosis. Once established, fibrosis is difficult to reverse and can permanently reduce erectile capacity.
This is the scientific rationale for penile rehabilitation: starting ED treatment early, even before spontaneous erections return, to preserve penile tissue health while the nerves recover.
The concept of penile rehabilitation was formalised by Montorsi and colleagues in a landmark 1997 study showing that intracavernosal alprostadil injections started soon after radical prostatectomy improved return of spontaneous erections.⁴ Since then, the evidence base has grown substantially.
Current rehabilitation protocols typically involve one or more of the following:
1. Oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil)
PDE5 inhibitors increase penile blood flow by blocking the enzyme that degrades cyclic GMP. In the rehabilitation context, low-dose daily tadalafil (5 mg) is often used to maintain oxygenation of erectile tissue between attempts. A Cochrane review found that early use of PDE5 inhibitors post-prostatectomy was associated with improved rates of erection recovery compared to on-demand use alone.⁵
2. Vacuum erection devices (VEDs)
A VED creates negative pressure around the penis, drawing blood into the corpora cavernosa. Regularly using a VED post-operatively helps preserve penile length and reduce fibrosis. It is particularly useful for men who cannot tolerate oral medications or in whom they are ineffective.
3. Intracavernosal injections (ICI)
For men with more significant nerve damage, direct injection of vasoactive agents (alprostadil alone or in combination with phentolamine and papaverine) into the penile shaft reliably produces erections regardless of nerve function. Success rates exceed 85% in most studies.⁶ ICI is considered the gold standard for post-prostatectomy erections when oral therapy fails.
4. Low-intensity shockwave therapy (Li-ESWT)
Emerging evidence supports Li-ESWT as a means of promoting neovascularisation and nerve regeneration. While not yet universally guideline-endorsed for post-prostatectomy ED specifically, multiple randomised controlled trials have shown improvements in erectile function scores.⁷
Recovery is not linear, and it varies considerably between individuals. The key predictors of erectile recovery after prostatectomy include:
A realistic framework, based on the EAU Guidelines on Sexual and Reproductive Health:⁸
| Timeframe | What to expect |
|---|---|
| 0–3 months post-op | Little to no spontaneous erection; focus on wound healing and rehabilitation start |
| 3–6 months | Some nocturnal tumescence may return in younger men with bilateral nerve-sparing |
| 6–12 months | Gradual improvement if rehabilitation has been consistent; ICI often needed for penetrative sex |
| 12–24 months | Maximum natural recovery window; outcomes plateau after 24 months |
ED after prostate cancer is never purely physical. Men commonly experience:
Psychosexual counselling, either individually or as a couple, is an underutilised but evidence-backed component of comprehensive ED rehabilitation. It should be offered alongside physical interventions, not as a last resort.
It is important to understand that PDE5 inhibitors work by enhancing the signal from the nervous system — a signal that, post-prostatectomy, may be severely diminished or absent. This is why standard ED medications have a lower response rate in post-prostatectomy patients than in the general ED population.
If oral medications are insufficient:
Q: Will my erections ever come back after prostate surgery?
A: For many men — particularly younger men who had bilateral nerve-sparing surgery and started rehabilitation early — significant return of erectile function is possible. However, full recovery is not guaranteed for everyone. Starting treatment early and consistently maximises your chances.
Q: How soon after surgery should I start ED treatment?
A: Most urologists recommend starting penile rehabilitation within 4–8 weeks of surgery, once catheter removal is confirmed and healing is underway. Earlier is generally better for tissue preservation.
Q: Are PDE5 inhibitors safe after prostate cancer?
A: Yes. PDE5 inhibitors act on erectile tissue, not on cancer cells, and there is no established evidence that they promote cancer recurrence. You should always consult your urologist before starting any new medication post-surgery.
Q: Does radiotherapy cause the same ED as surgery?
A: The mechanism differs. Post-radiotherapy ED is primarily vascular, tends to develop more gradually (over 1–2 years), and often responds better to oral PDE5 inhibitors than post-surgical ED does, since nerve function is usually intact.
Q: What if I have no sexual desire after hormone therapy?
A: Loss of libido on ADT is common and expected while testosterone is suppressed. After completing ADT, testosterone levels gradually recover — though this can take 6–18 months. A specialist can advise on whether testosterone levels have normalised and what options exist.
ED after prostate cancer treatment is a medical condition, not an inevitability you must simply accept. The earlier you engage with a specialist, the more options remain available.
At Noah, our doctors offer confidential, evidence-based consultations for men navigating sexual health challenges after cancer treatment. We understand the physical and emotional complexity of this experience.
Start a confidential consultation at ofnoah.sg →

